About Us
Glen Research, part of Maravai LifeSciences, is a leading provider of reagents for DNA and RNA oligonucleotide synthesis, labeling, and modification. Known for its proprietary Sterling™ line of reagents marked with its Sterling Seal of Quality Assurance, Glen analyzes and certifies these reagents for purity and performance ensuring consistent, dependable and reliable results. Glen also specializes in oligonucleotide purification supplies under the Glen-Pak™ and Glen Gel-Pak™ product lines.
Glen supplies its reagents to: researchers investigating diverse genetic diseases and disorders; businesses and organizations developing new genetic therapies; and, biopharmaceutical, diagnostic and life science OEM partners who incorporate Glen Research offerings into their own products.
Glen takes pride in delivering operational excellence, experienced technical support and superior customer service and is ISO 9001:2015 certified. As part of its Quality Management System, Glen verifies that its operations and processes meet all management criteria for consistency and performance.
Glen was founded in 1987 by Hugh and Margaret Mackie with a mission to provide state-of-the art reagents to researchers. In 1993, Glen introduced the Sterling line of products, a new standard of accomplishment for oligonucleotide synthesis.
Company Information
Andrew Murphy, Vice President, Site Operations
Andrew was appointed Vice President, Site Operations in 2023. He is responsible for all site operations including integrating business processes, regulatory compliance, information technology, and business continuity. He brings over thirty years of experience in chemistry and biotechnology manufacturing, operations management, product development, and quality management. He has held key leadership roles directly supporting Research and Development, Manufacturing, Quality Control, and Quality Assurance. He holds an M.S. in Biotechnology from Johns Hopkins University and a B.S. in Chemistry from University of Maryland.
Don Mallonee, Director of Commercial Operations
Don was appointed Director of Commercial Operations in 2019. He is responsible for global sales & marketing processes and initiatives. He brings twenty five years of implementing and leading commercial operations processes in the biotechnology industry with an emphasis in recombinant, and synthetic DNA/RNA technologies from his previous business management and progressive leadership roles at Celtrix Pharmaceuticals, Bayer Healthcare Berkeley for Fisher Scientific, Honeywell Research Chemicals and Avantor.
Don is a biologist with BS & MS degrees from Southern Illinois University at Carbondale.